BPC-157 peptide

Summary

BPC-157 is a lab-made chain of 15 amino acids (the building blocks of proteins) copied from part of a protein found in human gastric juice (stomach fluid). In rodents it consistently speeds tendon, ligament, muscle, and gut healing, but as of September 2026 there is no randomized human trial (one that assigns people to the drug or a placebo by chance) indexed in PubMed, so its evidence grade is animal-only. FDA removed it from the 503A Category 2 list (compounding ingredients flagged for significant safety risks) in April 2026 and its advisory committee recommended it for the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients) in July 2026, but a final listing has not been published.

What is BPC-157?

BPC-157 is a synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound. It is also known as Body Protection Compound 157, Pentadecapeptide BPC 157, BPC 157, BPC-157 arginate, Bepecin, PL 14736, BPC157, BPC-157 peptide.

How does it work?

In animal and cell models BPC-157 upregulates growth factor receptors (including EGR-1 and its repressor NAB2), increases nitric oxide system activity, and promotes angiogenesis through VEGFR2 signaling. It also increases fibroblast migration and outgrowth from tendon explants. These mechanisms are documented in rodent and in vitro work and have not been confirmed in humans.

BPC-157 benefits: what the evidence shows

Dozens of rodent studies from a small number of laboratories, mostly in Zagreb, report faster tendon, ligament, muscle, bone, and gastrointestinal healing, and a 2025 systematic review counted 35 preclinical studies and 1 clinical study in the musculoskeletal literature. Independent replication is limited. No randomized controlled trial in humans has been published as of the last verification date. The only indexed human data are three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety), which have no comparison group; they are listed but do not raise the grade.

Human evidence

No randomized controlled trial identified. Three small uncontrolled pilot reports from a single clinic are indexed: a retrospective phone survey of 16 people given knee injections (12 BPC-157 alone, 4 combined with thymosin beta-4), in which 14 reported relief; a pilot in 12 women with interstitial cystitis given a single bladder wall injection, all of whom reported improvement; and a 2 person intravenous safety pilot that found no changes in heart, liver, kidney, thyroid, or glucose markers. None had a control group, blinding, or long follow-up. A 2025 narrative review described human data as extremely limited, and a 2025 systematic review found no clinical safety data.

Animal evidence

In rats, BPC-157 accelerated Achilles tendon healing and increased tendon fibroblast outgrowth, survival, and migration in explant models. Rodent studies also report faster healing of transected muscle, ligament, bone, and gastrointestinal lesions, and protection against NSAID induced gut injury, given by injection, orally in drinking water, or topically. In rats and endothelial cells it increased blood vessel growth and VEGFR2 expression. A pharmacokinetic study in rats and dogs found an elimination half-life under 30 minutes after intravenous or intramuscular injection, with rapid breakdown into amino acids.

Key studies

Conditions studied

Is BPC-157 legal in the United States?

FDA and compounding status

Removed from the FDA 503A Category 2 list (substances with significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so state boards and pharmacies vary in whether they will compound it. It is not an FDA approved drug and is not eligible for 503B outsourcing.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

1. Sep 21, 2026WADA

   WADA publishes the 2027 Prohibited List

   WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

   Source: WADA 2027 Prohibited List
2. Jul 23, 2026PCAC

   PCAC recommends six peptides for the 503A bulks list

   At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend that BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon be added to the 503A bulk drug substances list. A committee recommendation is advisory; FDA must still issue a rule before the substances are formally listed.

   Regulatory: Under FDA reviewSource: Pharmacy Compounding Advisory Committee
3. Apr 15, 2026FDA

   FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

   FDA's Category 2 page, revised in April 2026 and current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. A withdrawn substance is no longer in 503A Category 2, but withdrawal is not an approval and does not place a substance on the 503A bulks list; a 503A pharmacy still needs a listing before it may compound it. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

   Regulatory: Removed from Category 2 (Apr 2026)Source: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)
4. Jan 1, 2026WADA

   WADA 2026 Prohibited List takes effect

   The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

   Source: WADA Prohibited List
5. Jan 1, 2025WADA

   WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

   The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 (TB-500), and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

   Source: WADA Prohibited List
6. Sep 2023FDA

   FDA places a batch of nominated peptides in 503A Category 2

   In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

   Regulatory: Not eligible for compoundingSource: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)
7. Jan 1, 2022WADA

   WADA 2022 Prohibited List adds BPC-157 as an S0 example

   The 2022 WADA Prohibited List took effect on January 1, 2022 and named BPC-157 as an example of a non-approved substance under section S0, making it prohibited at all times for athletes under the World Anti-Doping Code.

   Source: WADA Prohibited List

Full tracker for BPC-157 or the category-wide tracker.

What published studies of BPC-157 used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Rodent studies gave BPC-157 by injection, in drinking water, or topically; animal doses do not translate to a human dose, and no human dose finding study has been published.

Routes reported

BPC-157 side effects

Side effects

Interactions

Contraindications

How do people access BPC-157 legally?

Typical cost: No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.

• BPC-157 cost by channel
• Rules by state
• Verified provider directory

Compare BPC-157

• BPC-157 vs ARA-290 (cibinetide)
• BPC-157 vs GHK-Cu
• BPC-157 vs KPV
• BPC-157 vs TB-500

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make BPC-157 lawful. FDA's advisory committee recommended BPC-157 for the 503A bulks list in July 2026, but FDA has not published a final rule, so a pharmacy has no federal basis to compound it yet. [5] [6]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [15] [16] [17] [18] [19]

What changes for you

• No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]
• Identity, purity, sterility, and dose accuracy can vary from batch to batch. [17]
• Insurance rarely covers it, so you usually pay cash.
• For tested athletes, BPC-157 is prohibited at all times on the WADA list, whatever the source. [7]

What to check

These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:

• A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
• A real evaluation by a licensed prescriber, not just an online form.
• A certificate of analysis for the specific batch.

Blends that contain BPC-157

BPC-157 is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.

• GLOW: with GHK-Cu, TB-500 (thymosin beta-4). No lawful path.
• KLOW: with GHK-Cu, TB-500 (thymosin beta-4), KPV. No lawful path.
• Wolverine stack: with TB-500 (thymosin beta-4). Awaiting FDA final rule.

All peptide blends

Frequently asked questions

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

• BPC-157 before and after: reviews, results, and what controlled studies show

  BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.

• BPC-157 for gut health: the animal evidence and the missing human trials

  BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.

• BPC-157 human studies: every published report and registered clinical trial

  Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.

• BPC-157 nasal spray: what is and is not known about intranasal use

  No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status.

• Oral BPC-157: what capsules and pills were tested for, and what is missing

  Oral BPC-157 worked in rat gut, ligament, and fistula studies. No study has measured how much an oral capsule absorbs in people, and the two registered oral studies have posted no results.

• Are peptide injections safe? What is known and unknown

  FDA-approved peptide injections have documented side effects on their labels. Compounded and research-only peptides add unknowns: sterility, identity, dose accuracy, and contamination.

More on the blog

• How to get peptides prescribed legally in 2026
• Klow vs Glow peptide: what KPV adds and what is known
• Peptide before and after: trial results vs marketing photos
• Peptide stacks: what each common component has shown alone
• Peptides for muscle growth, ranked by human evidence
• What is peptide therapy? What clinics sell, what is legal, and what works
• How to read a peptide study
• PCAC recommended six peptides. What changes and what does not
• Peptides for tendon recovery, ranked by human evidence
• What are peptides? A plain-English guide

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.